Ivantis, Inc.

Dec 16, 2020

Ivantis Recognized For Innovation, Excellence And Company Culture

Nov 17, 2020

Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

Oct 10, 2019

Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent

Apr 23, 2019

Ivantis Announces Publication of Landmark Comparative MIGS Clinical Trial Results in Leading Ophthalmic Journal

Mar 14, 2019

Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial

Aug 13, 2018

Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS)

Apr 16, 2018

Ivantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial

Apr 12, 2018

New Data from the HORIZON Trial of the Hydrus® Microstent Shows Significantly Lower IOP and Medication Use at 24 Months in a US Patient Cohort

Nov 13, 2017

Ivantis FDA Clinical Trial of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials